ME Therapeutics is a biotechnology company that focuses on discovery & development of myeloid cell targeted immuno oncology drugs.
ME Therapeutics has raised $361K in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
ME Therapeutics's investors include National Research Council of Canada Industrial Research Assistance Program.
ME Therapeutics is headquartered in Vancouver, Canada.
ME Therapeutics is a biotechnology company that focuses on discovery & development of myeloid cell targeted immuno oncology drugs.
ME Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ME Therapeutics — Funding & Investors." VCBacked, June 3, 2026, https://www.vcbacked.co/company/me-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). ME Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/me-therapeutics
{{cite web |title=ME Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/me-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated